Even positive upstream and downstream AKT regulator transcripts, and oncogenic non-coding RNAs, such as miRNAs and lncRNAs, that target negative AKT regulators and show altered activity or levels in various cancers, as described in earlier sections of this review, could be targeted with such RNA-based modalities. The gene discussed is AKT1; the disease is cancer.